5-Hydroxymethyl-2′-deoxyuridine, but not temozolomide, enhances the selective synthetic lethality in BRCA1 and BRCA2-deficient cells caused by PARP inhibition

被引：1
|
作者：
Clement, Jean [1 ]
Nakamura, Jun [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4486
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells
    Groelly, Florian J.
    Dagg, Rebecca A.
    Petropoulos, Michalis
    Rossetti, Giacomo G.
    Prasad, Birbal
    Panagopoulos, Andreas
    Paulsen, Teressa
    Karamichali, Angeliki
    Jones, Samuel E.
    Ochs, Fena
    Dionellis, Vasilis S.
    Lombardi, Emilia Puig
    Miossec, Matthieu J.
    Lockstone, Helen
    Legube, Gaelle
    Blackford, Andrew N.
    Altmeyer, Matthias
    Halazonetis, Thanos D.
    Tarsounas, Madalena
    MOLECULAR CELL, 2022, 82 (18) : 3382 - +
  • [22] Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
    Bermes, Max
    Rodriguez, Maria Jimena
    de Toledo, Marcelo Augusto Szymanski
    Ernst, Sabrina
    Mueller-Newen, Gerhard
    Bruemmendorf, Tim Henrik
    Chatain, Nicolas
    Koschmieder, Steffen
    Baumeister, Julian
    Levantini, Elena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (24)
  • [23] Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
    Evers, Bastiaan
    Drost, Rinske
    Schut, Eva
    de Bruin, Michiel
    van der Burg, Eline
    Derksen, Patrick W. B.
    Holstege, Henne
    Liu, Xiaoling
    van Drunen, Ellen
    Beverloo, H. Berna
    Smith, Graeme C. M.
    Martin, Niall M. B.
    Lau, Alan
    O'Connor, Mark J.
    Jonkers, Jos
    CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3916 - 3925
  • [24] Targeting the PI3K Pathway Enhances the Effect of PARP-1 Inhibition in BRCA1 Deficient Breast Cancer Cells
    Kimbung, S.
    Aaltonen, K.
    Gruvberger-Saal, S.
    Berglund, P.
    Hedenfalk, I.
    CANCER RESEARCH, 2010, 70
  • [25] Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
    Clark, Caroline C.
    Weitzel, Jeffrey N.
    O'Connor, Timothy R.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1948 - 1958
  • [26] Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss
    Ding, Xia
    Sharan, Shyam K.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S441 - S442
  • [27] Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade
    Alblihy, Adel
    Ali, Reem
    Algethami, Mashael
    Ritchie, Alison A.
    Shoqafi, Ahmed
    Alqahtani, Shatha
    Mesquita, Katia A.
    Toss, Michael S.
    Ordonez-Moran, Paloma
    Jeyapalan, Jennie N.
    Dekker, Lodewijk
    Salerno, Martina
    Hartsuiker, Edgar
    Grabowska, Anna M.
    Rakha, Emad A.
    Mongan, Nigel P.
    Madhusudan, Srinivasan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [28] CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
    Xu, Hong
    Di Antonio, Marco
    McKinney, Steven
    Mathew, Veena
    Ho, Brandon
    O'Neil, Nigel J.
    Dos Santos, Nancy
    Silvester, Jennifer
    Wei, Vivien
    Garcia, Jessica
    Kabeer, Farhia
    Lai, Daniel
    Soriano, Priscilla
    Banath, Judit
    Chiu, Derek S.
    Yap, Damian
    Le, Daniel D.
    Ye, Frank B.
    Zhang, Anni
    Thu, Kelsie
    Soong, John
    Lin, Shu-chuan
    Tsai, Angela Hsin Chin
    Osako, Tomo
    Algara, Teresa
    Saunders, Darren N.
    Wong, Jason
    Xian, Jian
    Bally, Marcel B.
    Brenton, James D.
    Brown, Grant W.
    Shah, Sohrab P.
    Cescon, David
    Mak, Tak W.
    Caldas, Carlos
    Stirling, Peter C.
    Hieter, Phil
    Balasubramanian, Shankar
    Aparicio, Samuel
    NATURE COMMUNICATIONS, 2017, 8
  • [29] CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
    Hong Xu
    Marco Di Antonio
    Steven McKinney
    Veena Mathew
    Brandon Ho
    Nigel J. O’Neil
    Nancy Dos Santos
    Jennifer Silvester
    Vivien Wei
    Jessica Garcia
    Farhia Kabeer
    Daniel Lai
    Priscilla Soriano
    Judit Banáth
    Derek S. Chiu
    Damian Yap
    Daniel D. Le
    Frank B. Ye
    Anni Zhang
    Kelsie Thu
    John Soong
    Shu-chuan Lin
    Angela Hsin Chin Tsai
    Tomo Osako
    Teresa Algara
    Darren N. Saunders
    Jason Wong
    Jian Xian
    Marcel B. Bally
    James D. Brenton
    Grant W. Brown
    Sohrab P. Shah
    David Cescon
    Tak W. Mak
    Carlos Caldas
    Peter C. Stirling
    Phil Hieter
    Shankar Balasubramanian
    Samuel Aparicio
    Nature Communications, 8
  • [30] PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2
    Ramanathan, R.
    Wainberg, Z.
    Mina, L.
    Byers, L.
    Chugh, R.
    Zhang, C.
    Henshaw, J.
    Dorr, A.
    de Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S13 - S13
12345